Skip to main content
SpringerLink
Log in

Depot Antipsychotic Drugs

Place in Therapy

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 October 1994

Summary

The pharmacokinetics of depot antipsychotic medications are such that an intramuscular injection given at intervals of from 1 to 4 weeks will produce adequate plasma concentrations that are sufficient to prevent relapse over the dosage interval. Such medication is useful in patients who do not reliably take their oral medication. The pharmacokinetics and clinical actions of various depot formulations of antispychotic drugs have been extensively studied.

Unfortunately, patients who do not reliably take their oral medications are unlikely to volunteer for controlled studies. This is because the same factors that influence a patient to not cooperate with the physician in taking the medication as prescribed will also interfere with their willingness to volunteer for research protocols. Thus, evidence from blinded controlled trials may not necessarily reflect the actual patient population at risk.

We feel that particularly important evidence of efficacy of depot vs oral medication comes from mirror-image studies. In these trials, the number of hospitalisations after initiation of depot medication is compared with that observed when the patient was solely taking oral medication. Studies of this type show that depot medication substantially reduces the rate of relapse.

There is considerable evidence about how long depot medications should be used. For many patients, depot medication to prevent relapse in schizophrenia should be used for the life of the patient. As the conventional antispychotic agents are replaced by a new generation of agents, the need for depot formulations will continue, and the knowledge gained about the current formulations should transfer to future generations of drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aaes-Jorgensen T. Pharmacokinetics of three different injectable zuclopenthixol preparations. Progress in Neuropsychopharmacology and Biological Psychiatry 13: 77–85, 1989

    CAS  Google Scholar 

  • Aagrup-Andersson L, Bengtsson A, Erlandsson K, et al. Flupenthixol decanoate controlled investigation concerning dosage. Acta Psychiatrica Scandinavica 255 (Suppl.): 7–14, 1974

    Google Scholar 

  • Adamson L, Curry SH, Bridges PK, et al. Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine. Diseases of the Nervous System 33: 181–191, 1973 aiAddonizio G, Susman U. Neuroleptic malignant syndrome: a clinical approach, pp. 7–10, Mosby-Year Book Inc., St Louis, 1991

    Google Scholar 

  • Adelson D, Epstein LA. A study of phenothiazines in male and female chronically ill schizophrenics. Journal of Nervous and Mental Disease 134: 543–554, 1962

    PubMed  CAS  Google Scholar 

  • Andrews P, Hall JN, Snaith RP. Controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 128: 451–455, 1976

    PubMed  CAS  Google Scholar 

  • Astrup C, Grimsgard A, Hebnes K, et al. A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics. Acta Psychiatrica Scandinavica 50: 481–491, 1974

    PubMed  CAS  Google Scholar 

  • Baastrup PC, Ahlfors UG, Bjerkenstedt L, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica 87: 48–58, 1993

    PubMed  CAS  Google Scholar 

  • Bakke O. Clinical experience with depot neuroleptics. Acta Psychiatrica Scandinavica (Suppl. 246): 32–41, 1974

    Google Scholar 

  • Bankier RG. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenia psychosis. Journal of Clinical Pharmacology 13: 44–47, 1973

    CAS  Google Scholar 

  • Bankier RG, Pettit DE, Bergen B. A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients. Diseases of the Nervous System 29: 56–61, 1968

    PubMed  CAS  Google Scholar 

  • Baro F, Brugmans J, Dom R, et al. Maintenance therapy of chronic psychotic patients with a weekly oral dose of RI6341: a controlled double-blind study. Journal of Clinical Pharmacology 10: 3230–3241, 1970

    Google Scholar 

  • Barsa JA, Saunders JC. A double-blind study of fluphenazine enanthate. Diseases of the Nervous System 28: 496–498, 1967

    Google Scholar 

  • Benson PG. Hawthorne effect. In Corsini (Ed.) Encyclopedia of psychology, Vol. 2, pp. 94–95, John Wiley and Sons, New York, 1984

    Google Scholar 

  • Beresford R, Ward A. Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33: 31–49, 1987

    PubMed  CAS  Google Scholar 

  • Blackburn J, Allen J. Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. Journal of Nervous and Mental Disease 132: 303–307, 1961

    Google Scholar 

  • Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. British Journal of Psychiatry 121: 241–258, 1972

    PubMed  CAS  Google Scholar 

  • Bucci L, Fuchs M, Simeon J, et al. Depot fluphenazine in the treatment of psychosis in a community mental health clinic. Diseases of the Nervous System 31 (Suppl. 9): 28–31, 1970

    PubMed  Google Scholar 

  • Caffey EM, Diamond LS, Frank TV, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 17: 347–358, 1964

    PubMed  Google Scholar 

  • Capstick N. Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients. Acta Psychiatrica Scandinavica 61: 256–262, 1980

    PubMed  CAS  Google Scholar 

  • Carney MW, Sheffield BF. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. British Journal of Psychiatry 129: 476–481, 1976

    PubMed  CAS  Google Scholar 

  • Carney MW, Shefield BF. The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol. Current Medical Research Opinion 1: 423–426, 1973

    CAS  Google Scholar 

  • Carpenter WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry 147: 1138–1148, 1990

    PubMed  Google Scholar 

  • Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Statistical Methods in Medical Research 2: 161–172, 1993

    PubMed  CAS  Google Scholar 

  • Chang SS, Javaid UI, Dysken MW, et al. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 87: 55–58, 1985

    PubMed  CAS  Google Scholar 

  • Cheung HK. Schizophrenics fully remitted on neuroleptics for 3–5 years. British Journal of Psychiatry 138: 490–494, 1981

    PubMed  CAS  Google Scholar 

  • Chien CP, Cole JO. Drugs and rehabilitation in schizophrenia. In Greenblatt (Ed.) Drugs in combination with other therapies, pp. 13–24, Grune Stratton, New York, 1975

    Google Scholar 

  • Chouinard G, Annable L. Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry 133: 7, 1976

    Google Scholar 

  • Chouinard G, Annable I, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology 9: 247–253, 1989

    PubMed  CAS  Google Scholar 

  • Chouinard G, Annable L, Campbell W, et al. A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacology Bulletin 20: 108–109, 1984

    PubMed  CAS  Google Scholar 

  • Chouinard G, Annable L, Steinberg S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. Journal of Clinical Psychopharmacology 6: 21–26, 1986

    PubMed  CAS  Google Scholar 

  • Chouinard G, Ban TA, Lehmann HE, et al. Fluspirilene in the treatment of chronic schizophrenic patients. Current Therapeutic Research 12: 604–608, 1971

    Google Scholar 

  • Clark ML, Huber W, Hill D, et al. Pimozide in chronic outpatients. Diseases of the Nervous System 36: 137–141, 1975

    PubMed  CAS  Google Scholar 

  • Clark ML, Huber W, Serafetinides EA, et al. Pimozide (oral): a tolerance study. Clinical Trials Journal 2 (Suppl.): 25–32, 1971

    Google Scholar 

  • Cottrell WM, Magnus RV. Fluspirilene in schizophrenia. Journal of International Medical Research 1: 630–633, 1973

    Google Scholar 

  • Crawford R, Forrest A. Controlled trial of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry 124: 385–391, 1974

    PubMed  CAS  Google Scholar 

  • Crow TJ, MacMillan JF, Johnson AL, et al. A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148: 1207–127, 1986

    Google Scholar 

  • Curry S, Whelpton R, DeSchepper PJ. Plasma-fluphenazine concentration of long acting esters. Lancet 1: 1217–1218, 1978

    PubMed  CAS  Google Scholar 

  • Davis JM. Overview: maintenance therapy in psychiatry. 1: schizophrenia. American Journal of Psychiatry 132: 1237–1245, 1975

    PubMed  CAS  Google Scholar 

  • Davis JM; Dysken MW, Haberman SJ, et al. Use of survival curves in analysis of antipsychotic relapse studies, Advances in Biochemical Psychopharmacology 24: 471–481, 1980

    PubMed  CAS  Google Scholar 

  • Davis JM, Kane JM, Marder S, et al. Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry 54 (Suppl. 3): 24–30, 1993

    PubMed  Google Scholar 

  • De Schepper PJ, Vranckx C, Verbeek R, et al. Pipotiazine pharmacokinetics after p.o. and i.v. administration in man: correlation between blood levels and effect on the handwriting area. Arzneimittel Forschung 29: 1056–1062, 1979

    PubMed  Google Scholar 

  • Deberdt R, Elens P, Berghman W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule and plasma levels. Acta Psychiatrica Scandinavica 61: 356–363, 1980

    Google Scholar 

  • Deneker SJ, Frankenberg K, Malm U, et al. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes: evaluation of results at 6 and 12 months trial. Acta Psychiatrica Scandinavica (Suppl. 241): 101–118, 1973

    Google Scholar 

  • Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatrica Scandinavica 47: 420–430, 1973

    Google Scholar 

  • Devito RA, Brink L, Sloan C, et al. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. Journal of Clinical Psychiatry 39: 26–34, 1978

    PubMed  CAS  Google Scholar 

  • Diamond LS, Marks JB. Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage. Journal of Nervous and Mental Disease 131: 247–251, 1960

    PubMed  CAS  Google Scholar 

  • Dom R, DeMesmaecker L, van den Broucke, et al. Maintenance treatment of chronic schizophrenic patients: a study with the long-acting thioxanthene derivative, cis (Z)-clopenthixol decanoatesordinol depot. Acta Psychiatrica Scandinavica 57: 299-304, 1978

    PubMed  CAS  Google Scholar 

  • Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia: a long-term double-blind cross-over comparison. Acta Psychiatrica Scandinavica 74: 255–262, 1986

    PubMed  CAS  Google Scholar 

  • Ekland K, Forsman A. Low dose of haloperidol decanoate is effective against relapses in schizophrenic patients: a double-blind placebo controlled study. 17th Congress of the Collegium Internationale Neuro-Psychopharmacologica, Kyoto Japan, 10-14 September, 1990. Vol. 2, p. 287, 1990

  • Engelhardt DM, Rosen B, Freedman D, et al. Phenothiazines in the prevention of psychiatric hospitalization. Archives of General Psychiatry 16: 98–99, 1967

    PubMed  CAS  Google Scholar 

  • Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry 45 (Suppl.): 50–59, 1984

    PubMed  CAS  Google Scholar 

  • Ereshefsky L, Saklad SR, Tran-Johnson T, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacology Bulletin 26: 108–114, 1990

    PubMed  CAS  Google Scholar 

  • Ereshefsky I, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric patients. Biological Psychiatry 20: 329–332, 1985

    PubMed  CAS  Google Scholar 

  • Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine 8: 59–70, 1978

    PubMed  CAS  Google Scholar 

  • Falloon IRH, Boyd JL, McGill CW, et al. Family management in the prevention of exacerbations of schizophrenia: a controlled study. New England Journal of Medicine 306: 1437–1440, 1982

    PubMed  CAS  Google Scholar 

  • Frangos H, Zissis NP, Leontopoulos I, et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatrica Scandinavica 57: 436–446, 1978

    PubMed  CAS  Google Scholar 

  • Freeman H. Twelve years’ experience with the total use of depot neuroleptics in a defined population. Advances in Biochemical Psychopharmacology 24: 559–564, 1980

    PubMed  CAS  Google Scholar 

  • Freeman LS. Alson E. Prolonged withdrawal of chlorpromazine in chronic patients. Diseases of the Nervous System 23: 522–525, 1962

    PubMed  CAS  Google Scholar 

  • Gaebel W, Frick U, Linden M, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? British Journal of Psychiatry 163 (Suppl. 21): 8–12, 1993

    Google Scholar 

  • Gaebel W, Kopcke W, Linden OM, et al. 2-year outcome of intermittent vs maintenance neuroleptic treatment in schizophrenia. Schizophrenia Research 4: 288, 1991

    Google Scholar 

  • Garfield S, Gershon S, Sletten L, et al. Withdrawal of ataractic medication in schizophrenic patients. Diseases of the Nervous System 27: 321–325, 1966

    PubMed  CAS  Google Scholar 

  • Gerlach J, Kramp P, Kristjansen P, et al. Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 52: 132–144, 1975

    PubMed  CAS  Google Scholar 

  • Girard M, Granier F, Schmitt L, et al. Initial results of a pharmacokinetic study of pipothiazine and its palmitic ester (Piportil L4) in a schizophrenic population. Encephale 10: 171–176, 1984

    PubMed  CAS  Google Scholar 

  • Glazer WM. Depot fluphenazine: risk/benefit ratio. Journal of Clinical Psychiatry 45: 28–35, 1984

    PubMed  CAS  Google Scholar 

  • Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53:426–433, 1992

    PubMed  CAS  Google Scholar 

  • Goldberg SC, Schooler NR, Hogarty GE, et al. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry 34: 171–184, 1977

    PubMed  CAS  Google Scholar 

  • Goldstein MJ, Rodnick EH, Evans JR, et al. Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 35: 1169–1177, 1978

    PubMed  CAS  Google Scholar 

  • Gottfries CG, Green L. Flupenthixol decanoate in treatment of outpatients. Acta Psychiatrica Scandinavica 255: 15–24, 1974

    PubMed  CAS  Google Scholar 

  • Gravem A, Engstrand E, Guleng RJ. Cis(X)-clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. Acta Psychiatrica Scandinavica 58: 384–388, 1978

    PubMed  CAS  Google Scholar 

  • Gross HS. A double-blind comparison of once-a-day pimozide, trifluoperazine and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research 16: 696–705, 1974

    PubMed  CAS  Google Scholar 

  • Gross M, Reeves WP. Relapse after withdrawal of ataractic drugs in mental patients in transition. In Greenblatt (Ed.) Mental patients in transition, pp. 313–321, Charles C. Thomas, Springfield, 1961

    Google Scholar 

  • Guidice JD, Clark WG, Gocka EF, et al. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16: 32–36, 1975

    Google Scholar 

  • Haider I. A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. British Journal of Psychiatry 114: 837–841, 1968

    PubMed  CAS  Google Scholar 

  • Hershon HI, Kennedy PF, McGuire RJ. Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry 120: 40–50, 1972

    Google Scholar 

  • Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Clinical Neuropharmacology 13 (Suppl. 2): 426–427, 1990

    Google Scholar 

  • Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Archives of General Psychiatry 48: 333–339, 1991

    PubMed  CAS  Google Scholar 

  • Hirsch SR, Gaind R, Rohde PD, et al. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. British Medical Journal 1: 633–637, 1973

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Anderson CM, Reiss DJ, et al. Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia: II. two-year effect of controlled study on relapse and adjustment. Archives of General psychiatry 48: 340–347, 1991

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg SC. Collaborative study group. Drug and sociotherapy in the aftercare of schizophrenic patients: one-year relapse rates. Archives of General Psychiatry 28: 54–64, 1978

    Google Scholar 

  • Hogarty GE, Goldberg SC, Schooler NR, et al. Collaborative study group: drug and sociotherapy in the aftercare of schizophrenic patients. II: two-year relapse rates. Archives of General Psychiatry 31:603–608, 1974

    PubMed  CAS  Google Scholar 

  • Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Archives of General Psychiatry 45: 797–805, 1988

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluperazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36: 1238–1294, 1979

    Google Scholar 

  • Hogarty GE, Ulrich RE Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 34: 297–301, 1977

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF, Mussare F, et al. Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Diseases of the Nervous System 37: 494–500, 1976

    PubMed  CAS  Google Scholar 

  • Itil T, Heskiner A. Fluphenazine hydrochloride enanthate and decanoate in the management of chronic psychosis. Diseases of the Nervous System 31 (Suppl. 9): 37–42, 1970

    PubMed  Google Scholar 

  • Janssen PAJ, Niemegeers JE, Schellekens HJ, et al. The pharmacology of fluspirilene R 6218, a potent, long-acting and injectable neuroleptic drug. Arzneimittel Forschung 20: 1689–1698, 1970

    PubMed  CAS  Google Scholar 

  • Johnson DAW. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry 135: 524–530, 1979

    PubMed  CAS  Google Scholar 

  • Johnson DAW. Studies of depressive symptoms in schizophrenia. British Journal Psychiatry 139: 101, 1981

    Google Scholar 

  • Johnson DAW. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Journal of Clinical Psychiatry 5: 13–21, 1984

    Google Scholar 

  • Johnson DAW, Ludlow JM, Street K, et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized outpatients with schizophrenia. British Journal of Psychiatry 151: 634–638, 1987

    PubMed  CAS  Google Scholar 

  • Johnson DAW, Pasterski JM, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 67: 339–352, 1983

    PubMed  CAS  Google Scholar 

  • Johnson DAW, Wright NF. Drug prescribing for schizophrenic outpatients on depot injections: repeat surveys over 18 years. British Journal of Psychiatry 156: 827–834, 1990

    PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsh SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. British Medical Journal 301: 837–846, 1990

    PubMed  CAS  Google Scholar 

  • Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatients schizophrenics III: serum levels. Acta Psychiatrica Scandinavica 279 (Suppl. 61): 41–54, 1980

    Google Scholar 

  • Kane JM, Jeste DU, Barnes T, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association, p. 174, American Psychiatric Association, Washington, DC, 1992

    Google Scholar 

  • Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry 40: 893–896, 1983

    PubMed  CAS  Google Scholar 

  • Kinross-Wright J, Charalampoud KD. A controlled study of a very long-acting phenothiazine preparation. Neuropsychiatry 1: 66–70, 1965

    Google Scholar 

  • Kissling W. The current unsatisfactory state of relapse prevention in schizophrenic psychoses — suggestions for improvement. Clinical Neurophathology 2 (Suppl. 14): 533–544, 1991a

    Google Scholar 

  • Kissling W (Ed.) Guidelines for neuroleptic relapse prevention in schizophrenia, pp. 115–151, Springer-Verlag, Berlin, 1991b

    Google Scholar 

  • Kissling W, Moller HJ, Walter K, et al. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during six months’ treatment for relapse prevention. Pharmacopsychiatry 18: 240–245, 1985

    PubMed  CAS  Google Scholar 

  • Knudsen P, Bolvig-Hansen L, Larsen NE. Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical applications. Acta Psychiatrica Scandinavica 66 (Suppl. 322): 11–14, 1985

    Google Scholar 

  • Kurland AA, Dim BM, Olsson JE. The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics. Diseases of the Nervous System 31 (Suppl. 9): 18–23, 1970

    PubMed  Google Scholar 

  • Lapierre YD, Chaudhry R, Sipos V. A long-term efficacy and toxicity study of fluspirilene in chronic schizophrenia. Current Therapeutic Research 30: 793–802, 1981

    Google Scholar 

  • Larsson M, Axelsson R, Forsman A. On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Current Therapeutic Research 36: 1071–1088, 1984

    Google Scholar 

  • Leff J, Berkowitz R, Shavit N, et al. A trial of family therapy versus a relatives’ group for schizophrenia: two-year follow-up. British Journal of Psychiatry 157: 571–577, 1990

    PubMed  CAS  Google Scholar 

  • Leff J, Kuipers L, Berkowitz R, et al. Controlled trial of social intervention in the families of schizophrenic patients. British Journal of Psychiatry 141: 121–134, 1982

    PubMed  CAS  Google Scholar 

  • Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 3: 599–604, 1971

    PubMed  CAS  Google Scholar 

  • Levine J, Schooler N, Serene F, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication. Advances in Biochemical Psychopharmacology 24: 483–484, 1980

    PubMed  CAS  Google Scholar 

  • Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of National Cancer Institute 22: 719–748, 1959

    CAS  Google Scholar 

  • Marder R, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Archives of General Psychiatry 44: 518–521, 1987

    PubMed  CAS  Google Scholar 

  • Marder SR, Van Putten T, Aravagiri M, et al. Fluphenazine plasma levels and clinical response. Psychopharmacology Bulletin 26: 256–258, 1990

    PubMed  CAS  Google Scholar 

  • Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry 41: 1025–1029, 1984

    PubMed  CAS  Google Scholar 

  • Marriott P, Hiep A. A mirror image outpatient study at a depot phenothiazine clinic. Australian and New Zealand Journal of Psychiatry 10: 163, 1976

    PubMed  CAS  Google Scholar 

  • McCreadie R, Mackie M, Morrison D, et al. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry 140: 280–286, 1982

    PubMed  CAS  Google Scholar 

  • McLaren S, Cookson JC, Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. International Journal of Clinical Psychopharmacology 7: 67–72, 1992

    CAS  Google Scholar 

  • McNeil Pharmaceutical. New dosing guidelines: optimizing dosage reduces risk of relapse in chronic schizophrenia. McNeil Pharmaceutical, Raritan, 1993

  • Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients. Canadian Psychiatric Association Journal 11: 410–413, 1966

    Google Scholar 

  • Molcan J, Mayer A, Novotny V. Maintenance treatment with semidepot neuroleptic fluspirilene. Activatas Nervosa Superior 22: 163–164, 1980

    Google Scholar 

  • Moller-Nielsen I, Pedersen V, Nymark M, et al. The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmaceutica Nordica 33: 353–362, 1973

    Google Scholar 

  • Morgan R, Cheadle J. Maintenance treatment of chronic schizophrenia with neuroleptic drugs. Acta Psychiatrica Scandinavica 50:78–85, 1974

    PubMed  CAS  Google Scholar 

  • Morton MR. A study of withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 124: 1585–1588, 1968

    PubMed  CAS  Google Scholar 

  • Muller P, Bandelow B, Gaebel W, et al. Intermittent medication, coping and psychotherapy: interactions in relapse prevention and course modifications. British Journal of Psychiatry 161 (Suppl. 18): 140–144, 1992

    Google Scholar 

  • Nair NPU, Surany-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety and dosage equivalence. Journal of Clinical Psychopharmacology 6 (Suppl. 1): 305–375, 1986

    Google Scholar 

  • Nishikawa T, Tsida A, Tamala A. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 77: 301–304, 1982

    PubMed  CAS  Google Scholar 

  • Nymark M, Franck KF, Pederson V, et al. Prolonged neuroleptic effect of flupenthixol decanoate in oil. Acta Pharmaceutica Nordica 33: 363–376, 1973

    CAS  Google Scholar 

  • Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatrica Scandinavica 79: 564–570, 1989

    PubMed  CAS  Google Scholar 

  • Parent M, Toussaint C, Gilson H. Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation. Current Therapeutic Research 34 (1): 1–6, 1983

    Google Scholar 

  • Pinard G, Rosales D. Rapid stabilization of fluspirilene dosage in the treatment of the acute exacerbation of schizophrenics. Current Therapeutic Research 27: 419–428, 1980

    Google Scholar 

  • Pollack SL, Tourlentes TT, Zocchi AF. Clinical trial of fluphenazine enanthate — a long-acting injectable tranquilizer. Diseases of the Nervous System, July: 73–74, 1964

    Google Scholar 

  • Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia: report of the National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Archives of General Psychiatry 18: 482–495, 1968

    Google Scholar 

  • Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquilizing medication. British Journal of Psychiatry 115: 679–686, 1969

    PubMed  CAS  Google Scholar 

  • Rapp W, Hellban E, Norrman O, et al. A double-blind crossover study comparing haloperidol decanoate and perphenazine enanthate. Current Therapeutic Research 39: 665–670, 1986

    Google Scholar 

  • Rassidakis NC, Kodakis X, Papanastassiou A, et al. Withdrawal of antipsychotic drugs from chronic psychiatric patients. Bulletin of the Menninger Clinic 34: 216–222, 1970

    PubMed  CAS  Google Scholar 

  • Revaris CL, Weaver LA, Brooks GW. A controlled study of fluphenazine enanthate in chronic schizophrenic patients. Diseases of the Nervous System 26: 33–39, 1965

    Google Scholar 

  • Reynolds JEF (Ed.) Anxiolytic sedatives, hypnotics and neuroleptics. In Reynolds (Ed.) Martindale: the extra pharmacopoeia, 30th ed, pp. 364–623, Pharmaceutical Press, London, 1993

  • Reyntijens AJM, Heykants JJP, Woestenborghs RJH, et al. Pharmacokinetics of haloperidol decanoate. Pharmacopsychiatry 17: 238–246, 1982

    Google Scholar 

  • Rifkin A, Quitkin F, Rabiner CJ, et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics: I. relapse rate after one year. Archives of General Psychiatry 34: 43–47, 1977

    PubMed  CAS  Google Scholar 

  • Roelofs GA. Penfluridol (R16 341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation. Acta Psychiatrica Scandinavica 50: 219–224, 1974

    PubMed  CAS  Google Scholar 

  • Roose PE. Monthly haloperidol decanoate as a replacement for maintenance therapy. In Peris et al. (Eds) Proceedings of the Third World Congress Biological Psychiatry, p. F410, North Holland, Amsterdam, 1981

    Google Scholar 

  • Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. Journal of Nervous Mental Disorders 179: 212–214, 1991

    CAS  Google Scholar 

  • Schauver J, Gorham DR, Leskin LW, et al. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 20: 452–457, 1959

    Google Scholar 

  • Schiele BC. Loxapine succinate: a controlled double-blind study in chronic schizophrenia. Diseases of the Nervous System 36: 361–364, 1975

    PubMed  CAS  Google Scholar 

  • Schooler NR. Reduced dose and family management: impact and outcome. In Oldham & Riba (Eds) Continuing medical education syllabus and scientific proceedings. 146th Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27. American Psychiatric Association, Washington, p. 241, Abstract no. NRT22, 1993

  • Schooler NR, Levinei J, Severe JB. NIMH-PRB Collaborative Fluphenazine Study Group: depot fluphenazine in the prevention of relapse in schizophrenia. Evaluation of a treatment regimen. Psychopharmacology Bulletin 15: 44–47, 1979

    PubMed  CAS  Google Scholar 

  • Singh AN. Clinical evaluation of fluspirilene maintenance therapy in chronic schizophrenic patients. Canadian Psychiatric Association 18: 415–419, 1973

    CAS  Google Scholar 

  • St-Laurent J, Carle R, Domingue D. Fluspirilene in the treatment of chronic schizophrenic outpatients. Current Therapeutic Research 14: 599–608, 1972

    PubMed  CAS  Google Scholar 

  • Stephens JH, Astrup C. Prognosis in ‘process’ and ‘non-process’ schizophrenia. American Journal of Psychiatry 119:945–953, 1963

    Google Scholar 

  • Sterkmans P, Brugmans J, GeVers F. Clinical evaluation of fluspirilene (R6218): a long-acting injectable neuroleptic. Clinical Trials Journal 6: 19–25, 1969

    Google Scholar 

  • Svestka J, Nahunek K, Hadlik J, et al. Clinical experience with fluspirilene in psychoses. Activatas Nervosa Superior 13:173–174, 1971

    CAS  Google Scholar 

  • Tanghe A, Vereecken JL. Clinical and ergotherapeutic evaluation of fluspirilene (R 6218), a long-acting neuroleptic in chronic psychotic patients. Psychiatia, Neurologia, Neurochirurgia 74: 379–389, 1971

    CAS  Google Scholar 

  • Tanghe A, Vereecken JL. Fluspirilene, an injectable, and penfluridol, an oral long-acting neuroleptic: a comparative double-blind trial in residual schizophrenia. Acta Psychiatrica Scandinavica 48:315–331, 1972

    PubMed  CAS  Google Scholar 

  • Tarrier N, Barrowclough C, Vaughn C, et al. The community management of schizophrenia. British Journal of Psychiatry 153: 532–542, 1988

    PubMed  CAS  Google Scholar 

  • Tegeler J, Lehmann E. A follow-up study of schizophrenic outpatients treated with depot neuroleptics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 5: 79–90, 1981

    CAS  Google Scholar 

  • Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazine in the aftercare of schizophrenic patients. Pennsylvania Psychiatric Quarterly 2: 11–15, 1962

    Google Scholar 

  • Trueman HR, Valentine ME. Flupenthixol decanoate in schizophrenia. British Journal of Psychiatry 124: 58–59, 1974

    PubMed  CAS  Google Scholar 

  • Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. British Journal of Psychiatry 129: 125–137, 1976

    PubMed  CAS  Google Scholar 

  • Vaughn CE, Snyder KS, Jones S, et al. Family factors in schizophrenic relapse. Archives of General Psychiatry 41: 1169–1177, 1984

    PubMed  CAS  Google Scholar 

  • Vereecken JL, Tanghe A. Fluspirilene and pipothiazine, two long-acting injectable neuroleptics: a double-blind controlled trial in residual schizophrenia. Psychiatrica, Neurologia, Neurochirurgica 75: 117–127, 1972

    CAS  Google Scholar 

  • Villeneuve A, Dogan K, Lachance R, et al. A controlled study of fluspirilene in chronic schizophrenia. Current Therapeutic Research 12: 819–827, 1970

    PubMed  CAS  Google Scholar 

  • Viukari M, Sato H, Lanninsuin U, et al. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatrica Scandinavica 65: 301–308, 1982

    PubMed  CAS  Google Scholar 

  • Whitaker CB, Hoy RM. Withdrawal of perphenazine in chronic schizophrenia. British Journal of Psychiatry 109: 422–427, 1963

    Google Scholar 

  • Wistedt B. A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 64: 65–84, 1981

    PubMed  CAS  Google Scholar 

  • Wistedt B, Persson T, Hellbom E. A clinical double-blind comparison between haloperidol decanoate. Current Therapeutic Research 35: 804–813, 1984

    Google Scholar 

  • Wistedt B, Ranta J. Comparative double-blind study of flupenthixol decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatrica Scandinavica 67: 378–388, 1983

    PubMed  CAS  Google Scholar 

  • Woolf B. On estimating the relationship between blood group and disease. Annals of Human Genetics 19: 251–253, 1995

    Google Scholar 

  • Youssef HA. A five-year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanoate versus other neuroleptics. Advances in Therapy 64:186–195, 1989

    Google Scholar 

  • Zissis NP, Psaras M, Lyketsos G. Haloperidol decanoate a new long-acting antipsychotic in chronic schizophrenics: double-blind comparison with placebo. Current Therapeutic Research 31: 650–655, 1982

    Google Scholar 

  • Zuardi Aw, Giampietro AC, Grassi ER, et al. Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Current Therapeutic Research 34: 253–261, 1982

    Google Scholar 

  • Zwanikken GJ, Remans B, Dewuof P, et al. Clinical evaluation of the long-acting injectable neuroleptic, fluspirilene, in the treatment of schizophrenic and mentally retarded patients. Acta Psychiatrica Scandinavica 47: 334–348, 1971

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Illinois, Chicago, Illinois, USA

    John M. Davis (MD) & Lesley Blake

  2. School of Medicine, University of Illinois, Chicago, Illinois, USA

    Leor Metalon

  3. Department of Pharmacy Practice, University of Illinois, Chicago, Illinois, USA

    Mark D. Watanabe

Authors
  1. John M. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leor Metalon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark D. Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lesley Blake
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259620.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, J.M., Metalon, L., Watanabe, M.D. et al. Depot Antipsychotic Drugs. Drugs 47, 741–773 (1994). https://doi.org/10.2165/00003495-199447050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199447050-00004

Keywords

Search

Navigation